Table 4. The 25 significantly enriched (α ≤ 0.05) sex-biased KEGG pathways.
| Adj p value | KEGG ID | KEGG name | No. of genes | Differentially expressed genes |
|---|---|---|---|---|
| 5.41E-3 | KEGG:05165 | Human papillomavirus infection | 29 | DVL3, IKBKG, HDAC5, PPP2R5C, HDAC2, PSEN1, PPP2CA, RPS6KB1, PPP2R5E, SCRIB, IFNAR1, HDAC3, TCF7L2, UBE3A, LAMC1, RBL1, PIK3R3, FADD, ATP6V1H, ITGA2B |
| 5.41E-3 | KEGG:04144 | Endocytosis | 23 | AP2A2, RAB8A, KIF5B, GIT1, CYTH1, RAB5A, VPS26A, RUFY1, TFRC, USP8, CHMP5, SH3GL3, WAS, VPS35, ARAP1, SNX2, PRKCI, WIPF2, CLTC, ARF1 |
| 3.17E-3 | KEGG:04141 | Protein processing in endoplasmic reticulum | 18 | SEC24B, DNAJB1, DERL3, UBE2G2, NFE2L2, HSP90B1, HSP90AA1, SSR1, DNAJC3, PDIA4, HSPA5, SEC62, PLAA, EIF2AK1, EIF2AK3, DNAJA2, SEC24A, NPLOC4 |
| 5.41E-3 | KEGG:04530 | Tight junction | 16 | MARVELD3, RAC1, RAB8A, ACTR2, PPP2CA, HSPA4, SCRIB, ACTR3, ACTB, WAS, MYL12B, RAPGEF6, PRKCI, PPP2R2D, PATJ, ERBB2 |
| 2.60E-2 | KEGG:04151 | PI3K-Akt signaling pathway | 16 | RAC1, PPP2R5C, YWHAB, YWHAH, HSP90B1, PPP2CA, RPS6KB1, HSP90AA1, PDPK1, EIF4E, PIK3R3, ITGA2B, PIK3R1, PPP2R2D, ERBB2, MAPK1 |
| 3.17E-3 | KEGG:05164 | Influenza A | 15 | TRIM25, DNAJB1, KPNA2, XPO1, IFNAR1, IFIH1, PIK3R3, ACTB, EIF2AK3, OAS3, HNRNPUL1, PIK3R1, NXT2, MAPK1, CYCS |
| 1.95E-2 | KEGG:05168 | Herpes simplex infection | 14 | PPP1CB, CDK1, HCFC2, CDC34, USP7, IFNAR1, CSNK2B, TAF5, IFIH1, FADD, EIF2AK3, OAS3, CYCS, CSNK2A1 |
| 2.11E-2 | KEGG:03013 | RNA transport | 14 | PHAX, PABPC4, NUP50, XPO1, ACIN1, RANGAP1, DDX20, EIF4E, NCBP1, UPF3B, NXT2, THOC7, EIF2S2, EIF4EBP3 |
| 4.19E-2 | KEGG:05225 | Hepatocellular carcinoma | 14 | SMARCB1, DVL3, NFE2L2, RPS6KB1, SMARCD1, TCF7L2, SMARCC2, ACTL6A, PIK3R3, ACTB, PIK3R1, MAPK1, SMARCD2, RPS6KB2 |
| 1.16E-2 | KEGG:03040 | Spliceosome | 14 | PUF60, PRPF31, EFTUD2, DDX46, ACIN1, PLRG1, NCBP1, SRSF10, SYF2, SRSF9, USP39, PPIH, PRPF4, SF3B4 |
| 8.13E-3 | KEGG:04120 | Ubiquitin mediated proteolysis | 14 | CUL3, UBE2G2, BRCA1, HERC4, FBXW11, CDC34, HUWE1, UBE3A, CUL4A, BIRC3, CUL5, PIAS1, UBA6, UBA2 |
| 5.41E-3 | KEGG:04140 | Autophagy—animal | 13 | PPP2CA, RPS6KB1, PDPK1, MLST8, RRAGD, PIK3R3, EIF2AK3, ATG2B, PIK3R1, ATG16L2, MAPK1, HMGB1, NRBF2 |
| 1.38E-3 | KEGG:05169 | Epstein-Barr virus infection | 13 | POLR3D, YWHAB, YWHAH, HDAC2, CDK1, PSMC6, USP7, PSMD14, POLR3C, PIK3R3, RBPJ, PIK3R1, CSNK2A1 |
| 1.95E-2 | KEGG:04510 | Focal adhesion | 12 | RAC1, PPP1CB, PDPK1, FLNB, PIK3R3, ACTB, BIRC3, ITGA2B, MYL12B, PIK3R1, ERBB2, MAPK1 |
| 2.03E-2 | KEGG:05160 | Hepatitis C | 12 | IKBKG, PPP2CA, IFNAR1, PDPK1, PIK3R3, EIF2AK1, EIF2AK3, PIAS1, OAS3, PIK3R1, PPP2R2D, MAPK1 |
| 5.41E-3 | KEGG:03015 | mRNA surveillance pathway | 12 | RNMT, PABPC4, PPP1CB, PPP2R5C, PPP2CA, PPP2R5E, ACIN1, ETF1, NCBP1, UPF3B, PPP2R2D, NXT2 |
| 2.63E-2 | KEGG:04152 | AMPK signaling pathway | 11 | RAB8A, PPP2R5C, PPP2CA, RPS6KB1, PPP2R5E, HMGCR, PDPK1, PIK3R3, PIK3R1, PPP2R2D, RPS6KB2 |
| 2.03E-2 | KEGG:04390 | Hippo signaling pathway | 11 | DVL3, PPP1CB, YWHAB, YWHAH, FBXW11, PPP2CA, SCRIB, ACTB, PPP2R2D, MOB1A, PATJ |
| 1.38E-3 | KEGG:05203 | Viral carcinogenesis | 11 | GTF2H1, MAPKAPK2, YWHAB, CDK1, GTF2A1, USP7, UBE3A, PIK3R3, RBPJ, PIK3R1, MAPK1 |
| 8.13E-3 | KEGG:05212 | Pancreatic cancer | 10 | RAC1, IKBKG, RALA, RPS6KB1, PIK3R3, BRCA2, PIK3R1, ERBB2, MAPK1, RPS6KB2 |
| 1.38E-3 | KEGG:04114 | Oocyte meiosis | 10 | PPP1CB, PPP2R5C, YWHAB, YWHAH, CDK1, PPP3CB, SLK, MAD2L1, PPP3R1, MAPK1 |
| 8.02E-3 | KEGG:04910 | Insulin signaling pathway | 10 | PPP1CB, RPS6KB1, PRKAR1A, PDPK1, PTPN1, EIF4E, PIK3R3, PKLR, PIK3R1, MAPK1 |
| 1.56E-2 | KEGG:05210 | Colorectal cancer | 10 | RAC1, MSH6, RALA, RPS6KB1, TCF7L2, PIK3R3, PIK3R1, MAPK1, CYCS, RPS6KB2 |
| 1.12E-2 | KEGG:03008 | Ribosome biogenesis in eukaryotes | 9 | XPO1, CSNK2B, RBM28, MPHOSPH10, XRN1, TBL3, NXT2, CSNK2A1, RIOK2 |
| 8.13E-3 | KEGG:05170 | Human immunodeficiency virus 1 infection | 8 | CDK1, RPS6KB1, PIK3R3, FADD, CUL4A, PPP3R1, MAPK1, CYCS |
The 25 significantly enriched (α ≤ 0.05) sex-biased KEGG pathways (Kyoto Encyclopedia of Genes and Genomes) that have the highest number of differentially expressed genes (significance based on adjusted p values). For the complete list of 79 pathways see S4 Table.